Overview

A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies

Status:
Completed
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, safety study. Eligible subjects will be adults with advanced malignancies. The study includes a pretreatment and treatment phase. The pretreatment phase consists of screening and baseline periods. The treatment phase consists of 4-week treatment periods and a follow-up period.
Phase:
Phase 1
Details
Lead Sponsor:
Athenex, Inc.
Kinex Pharmaceuticals Inc
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel